Placebo Matching Mitapivat + Mitapivat
Phase 3Active 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Transfusion-dependent Alpha-Thalassemia
Conditions
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Trial Timeline
Dec 20, 2021 → Dec 1, 2028
NCT ID
NCT04770753About Placebo Matching Mitapivat + Mitapivat
Placebo Matching Mitapivat + Mitapivat is a phase 3 stage product being developed by Agios Pharmaceuticals for Non-Transfusion-dependent Alpha-Thalassemia. The current trial status is active. This product is registered under clinical trial identifier NCT04770753. Target conditions include Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04770753 | Phase 3 | Active |
| NCT04770779 | Phase 3 | Active |
Competing Products
2 competing products in Non-Transfusion-dependent Alpha-Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 25 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 25 |